Amarin reported $443.62M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amarin USD 443.62M 5.8M Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
DBV Technologies USD 160.4M 47.5M Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026